Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Biochem Pharmacol ; 193: 114767, 2021 11.
Artigo em Inglês | MEDLINE | ID: mdl-34537248

RESUMO

Homologous recombination repair (HRR) is crucial for genomic stability of cancer cells and is an attractive target in cancer therapy. Holliday junction (HJ) is a four-way DNA intermediate that performs an essential role in homology-directed repair. However, few studies about regulatory mechanisms of HJs have been reported. In this study, to better understand the biological effects of HJs, VE-822 was identified as an effective DNA HJ stabilizer to promote the assembly of HJs both in vitro and in cells. This compound could inhibit the HRR level, activate DNA-PKCS to trigger DNA damage response (DDR) and induce telomeric DNA damage via stabilizing DNA HJs. Furthermore, VE-822 was demonstrated to sensitize the osteosarcoma cells to doxorubicin (Dox) by enhancing DNA damage and cellular apoptosis. This work thus reports one novel HJ stabilizer, and provide a potential anticancer strategy through the modulation of DNA HJs.


Assuntos
Dano ao DNA/efeitos dos fármacos , Reparo do DNA/efeitos dos fármacos , DNA/genética , Isoxazóis/farmacologia , Osteossarcoma/tratamento farmacológico , Pirazinas/farmacologia , Recombinação Genética , Antineoplásicos/uso terapêutico , Linhagem Celular Tumoral , DNA/química , Doxorrubicina/uso terapêutico , Humanos , Osteossarcoma/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA